Clinical Trial Update: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and potential efficacy of allogeneic NK cell infusions in adults with relapsed/refractory acute myeloid leukemia and high-risk my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Allogeneic NK cell infusion (allogeneic natural killer cells)

Snippet

Sponsor: Coeptis Therapeutics | Conditions: AML, Adult Recurrent, MDS | Phase 1 | Status: COMPLETED